Auxly Cannabis Group Inc (XLY) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Auxly Cannabis Group Inc stock C$5.74, price C$3.53, upside +62.6%, quality 77 out of 100. Rating: strongly undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Auxly Cannabis Group Inc
XLY · TOCheap (38% below fair value), strong company and rising price: meets all 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.
How to read this chart
60‑month range C$0.1400 – C$4.69 · fair‑value band C$2.86 – C$7.24 · the C$3.53 price screens below the C$5.74 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 15, 2026.
Every Wednesday you see whether Auxly Cannabis Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Auxly Cannabis Group Inc. operates as a consumer-packaged goods company in the cannabis products market in Canada. The company offers dried and fresh cannabis, plants, seeds, and oils; and edibles, extracts, and topicals under the KOLAB PROJECT, Dosecann, BACK FORTY, Foray, and Parcel brand names.
Show moreShow less
It sells its products through supply arrangements with provincial control boards and distributors, medical cannabis sales channels, and retailers, as well as to authorized wholesalers.
The company was formerly known as Cannabis Wheaton Income Corp. and changed its name to Auxly Cannabis Group Inc. in June 2018. Auxly Cannabis Group Inc. was incorporated in 1987 and is headquartered in Toronto, Canada.
Stock analysis
Auxly Cannabis Group Inc (XLY) currently trades at C$3.53, while our model-based Fair Value estimate is C$5.74, implying the stock looks roughly 38% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of C$18.84 per share, and 20 of the 24 models we run sit above the C$3.53 price.
Bear case: the Economic Profit group reads lowest at C$2.61, and 4 of the 24 models stay below the price. Data coverage for this calculation is high.
Scenario range: C$2.86 (bear) to C$7.24 (bull), the price of C$3.53 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 77/100 (high quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Auxly Cannabis Group Inc reported revenue of C$151M in FY2025 versus C$83.8M in FY2021, a compound +15.9%/yr. Reported net income was C$41.9M in FY2025.
Key figures
Market cap C$414M (≈ $289M) Micro · P/E ratio 14.7 · P/S ratio 4.06 · EPS (TTM) C$0.2400 · Net margin 27.6% · Return on equity 20.2% · Return on assets (EBIT) −3.1% (5-year average) · Operating margin 18.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 73 out of 100 (low confidence).
What moves the price
The share trades about 6% below its 52-week high and 119% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 63%, XLY screens cheaper than that median.
Fair Value models
All 24 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
Watch XLY, get fair value alerts →
Compare Auxly Cannabis Group Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Return on assets by industry
- Fair value gap by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: Canadian Stocks
- Valuation of the Canada market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $84.39 | $113.53 | +35% | vs XLY |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥48.02 | ¥53.04 | +10% | vs XLY |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,868 | ₹1,983 | +6% | vs XLY |
| Haleon plc HLN | $9.20 | $8.47 | −8% | vs XLY |
| Merck KGaA MRK | €149.70 | €108.83 | −27% | vs XLY |
| Galderma Group GALD | CHF 191.00 | CHF 112.46 | −41% | vs XLY |
| Takeda Pharmaceutical Company TAK | $21.59 | $11.23 | −48% | vs XLY |
| Teva Pharmaceutical Industries Limited TEVA | $42.57 | $20.74 | −51% | vs XLY |
| Sandoz Group SDZ | CHF 84.60 | CHF 40.54 | −52% | vs XLY |
| Divi's Laboratories Limited DIVISLAB | ₹11,080 | ₹1,567 | −86% | vs XLY |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Auxly Cannabis Group Inc (XLY) overvalued or undervalued?
What is the fair value of XLY?
What is the quality score of XLY?
What is the price target for Auxly Cannabis Group Inc (XLY)?
What is the Auxly Cannabis Group Inc stock forecast for 2026?
What is the revenue of Auxly Cannabis Group Inc (XLY)?
What growth is priced into Auxly Cannabis Group Inc (XLY)?
What discount rate (WACC) does the fair value of XLY use?
What is a reverse DCF?
How much growth has Auxly Cannabis Group Inc (XLY) delivered so far?
How fast is the sector of Auxly Cannabis Group Inc (XLY) growing?
What is the free cash flow yield of Auxly Cannabis Group Inc (XLY)?
What is the intrinsic value of Auxly Cannabis Group Inc (XLY)?
Is Auxly Cannabis Group Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of XLY?
How much is Auxly Cannabis Group Inc worth?
What do the bullish and bearish scenarios say about XLY?
What is the P/E ratio of XLY?
How solid is the balance sheet of Auxly Cannabis Group Inc (XLY)?
How far is XLY from its 52-week high?
Which stocks are comparable to Auxly Cannabis Group Inc?
Is Auxly Cannabis Group Inc stock attractive at the current price?
How is the fair value of XLY calculated?
Is it still worth investing in stocks now?
What is the share price of Auxly Cannabis Group Inc (XLY)?
What should I pay attention to with Auxly Cannabis Group Inc right now?
Key figures of Auxly Cannabis Group Inc
How large is the market capitalisation of Auxly Cannabis Group Inc (XLY)?
What is the P/S ratio of Auxly Cannabis Group Inc (XLY)?
What are the earnings per share of Auxly Cannabis Group Inc (XLY)?
What is the net margin of Auxly Cannabis Group Inc (XLY)?
What is the return on equity of Auxly Cannabis Group Inc (XLY)?
What is the EBIT return on assets of Auxly Cannabis Group Inc (XLY)?
What is the operating margin of Auxly Cannabis Group Inc (XLY)?
How fast is revenue growing at Auxly Cannabis Group Inc (XLY)?
How fast are earnings growing at Auxly Cannabis Group Inc (XLY)?
How much net debt does Auxly Cannabis Group Inc (XLY) carry?
Watch Auxly Cannabis Group Inc in the live analysis
One click puts Auxly Cannabis Group Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.